Trial Profile
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2023
Price :
$35
*
At a glance
- Drugs TAEST 16001 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Osteosarcoma; Soft tissue sarcoma
- Focus Adverse reactions
- 11 Apr 2023 Planned End Date changed from 15 Feb 2023 to 15 May 2024.
- 11 Apr 2023 Planned primary completion date changed from 15 Feb 2023 to 15 Feb 2024.
- 11 Apr 2023 Status changed from recruiting to active, no longer recruiting.